#Reyataz

That’s compared with HIV-negative men.

A recent study compared birth outcomes among HIV-positive women exposed to various antiretroviral regimens.

Investigators behind the recent study that raised this concern suggest not combining the two until more research can be done.

A recent analysis of Europeans taking boosted protease inhibitors for HIV treatment found this pair prompted the best long-term response.

This marks the manufacturer’s fifth generic antiretroviral launch.

In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.

Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.

A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.

The company is losing its exclusive rights to two HIV drugs: Reyataz and Sustiva.

This is according to a large study of U.S. veterans.

The two-drug regimen can cure the virus in as little as eight weeks.

The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Combo treatment with fine-particle formulations of Reyataz and Norvir, plus an immune-dampener drug, greatly reduced HIV levels in mice.

A two-drug regimen of Norvir (ritonavir)Ã¢€“boosted Reyataz (atazanavir) and Epivir (lamivudine) treats HIV as well or better tha...

Research of Bristol-Myers Squibb’s BMS-955176, an HIV maturation inhibitor, has shown the antiretroviral is potent and well-tolerated.